Wall Street analysts expect that Mesa Laboratories, Inc. (NASDAQ:MLAB) will report earnings of $1.48 per share for the current quarter, according to Zacks. Three analysts have provided estimates for Mesa Laboratories’ earnings. The lowest EPS estimate is $1.38 and the highest is $1.63. Mesa Laboratories reported earnings of $1.29 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 14.7%. The business is scheduled to announce its next quarterly earnings report on Monday, June 7th.
On average, analysts expect that Mesa Laboratories will report full-year earnings of $6.27 per share for the current financial year, with EPS estimates ranging from $4.97 to $7.02. For the next financial year, analysts expect that the firm will post earnings of $6.73 per share, with EPS estimates ranging from $5.39 to $7.43. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that follow Mesa Laboratories.
Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings results on Wednesday, February 3rd. The medical instruments supplier reported $0.76 earnings per share for the quarter, missing analysts’ consensus estimates of $1.27 by ($0.51). Mesa Laboratories had a positive return on equity of 6.39% and a negative net margin of 2.04%. The firm had revenue of $34.17 million for the quarter, compared to analyst estimates of $32.30 million.
In other Mesa Laboratories news, Director John Bradley Schmieder sold 1,750 shares of the stock in a transaction on Wednesday, February 10th. The stock was sold at an average price of $278.23, for a total transaction of $486,902.50. Following the completion of the transaction, the director now directly owns 71,717 shares of the company’s stock, valued at $19,953,820.91. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Brian David Archbold sold 223 shares of the stock in a transaction on Wednesday, March 10th. The shares were sold at an average price of $271.78, for a total value of $60,606.94. Following the transaction, the senior vice president now directly owns 377 shares of the company’s stock, valued at $102,461.06. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,193 shares of company stock valued at $2,216,028. 6.10% of the stock is currently owned by corporate insiders.
Institutional investors have recently bought and sold shares of the company. Veriti Management LLC bought a new position in shares of Mesa Laboratories in the fourth quarter worth $44,000. Nisa Investment Advisors LLC raised its position in shares of Mesa Laboratories by 600.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 525 shares of the medical instruments supplier’s stock worth $150,000 after buying an additional 450 shares in the last quarter. Cresset Asset Management LLC purchased a new stake in shares of Mesa Laboratories in the fourth quarter worth $215,000. Amalgamated Bank purchased a new stake in shares of Mesa Laboratories in the fourth quarter worth $224,000. Finally, Trexquant Investment LP purchased a new stake in shares of Mesa Laboratories in the fourth quarter worth $243,000. 93.54% of the stock is owned by hedge funds and other institutional investors.
Shares of Mesa Laboratories stock traded up $4.44 on Wednesday, hitting $256.75. The company had a trading volume of 13,990 shares, compared to its average volume of 27,276. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -366.79 and a beta of 0.39. Mesa Laboratories has a 1 year low of $207.54 and a 1 year high of $307.97. The stock has a 50 day moving average of $254.49 and a 200-day moving average of $273.03. The company has a debt-to-equity ratio of 0.36, a quick ratio of 13.74 and a current ratio of 14.34.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 15th. Stockholders of record on Monday, May 31st will be issued a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.25%. The ex-dividend date of this dividend is Thursday, May 27th. Mesa Laboratories’s dividend payout ratio is presently 15.20%.
About Mesa Laboratories
Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products in the United States, Canada, Europe, and Japan. The company's Sterilization and Disinfection Control segment manufactures and markets biological indicators comprising spore strips, self-contained products, and culture media, as well as process challenge devices; and offers testing services.
Recommended Story: Retained Earnings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.